Catalyst
Slingshot members are tracking this event:
FDA Designates Merck's (MRK) KEYTRUDA a Breakthrough Therapy for Treatment of Microsatellite Instability High Metastatic Colorectal Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cncr, Keytruda, Metastatic Colorectal Cancer, Pd-1 Inhibitor, Microsatellite Instability High
